Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone PCA for perioperative analgesia of TACE
ChiCTR2500110652Phase 4Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of hydromorphone in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Mean pain score. Started Oct 2025; status: completed.
02
Drugs
hydromorphone
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500110652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110652.